OncoPrecision (United States)

OncoPrecision is an oncology therapeutics company based in New York, United States. According to its official website, the company is focused on developing precision medicines intended to give patients transformational options, guided by their biology and defined by their lives. Its stated mission centers on blood cancers and hard-to-treat solid tumors, areas where the company argues that lives are cut short not for lack of effort but for lack of therapies that reach the right biology at the right time. The company describes a differentiated discovery approach built on what it calls three forces converging on one mission. The first is patient-derived biology: OncoPrecision states that its targets are identified from real patient tumor biology rather than population databases, and that it starts where resistance is already happening. The second is AI-enhanced discovery, in which computational modeling is used to accelerate target validation and antibody optimization, compressing the timeline from insight to clinical candidate. The third is what the company calls first-in-class audacity: antibody-drug conjugates and bispecific antibodies engineered to exploit vulnerabilities that existing therapies cannot reach, with CD64 named as an initial focus. OncoPrecision presents itself as a company building medicines with a higher probability of clinical success by starting at the center of the convergence of these three forces. Its public-facing materials emphasize a patient-first narrative, including the trademarked Patient Micro-Avatars™ platform concept, which is positioned as a way to identify targets from real patient tumor biology. The company's pipeline and science pages are highlighted on its homepage as the primary entry points for visitors. As of the available evidence, OncoPrecision is an active company in New York, United States. Detailed corporate information such as founding year, founders, ownership structure, funding, and listing status is not provided in the supplied sources, and no such details are asserted here.

OncoPrecision is an oncology therapeutics company located in New York, United States. The available evidence does not specify a founding date, founding team, or detailed corporate history. What is documented is the company's current public positioning: it describes itself as developing precision medicines to give patients transformational options, guided by their biology and defined by their lives. The company's stated focus is on blood cancers and hard-to-treat solid tumors. OncoPrecision argues that these diseases cut short too many lives not for lack of effort but for lack of therapies that reach the right biology at the right time, and it frames its work as building those therapies. Its homepage emphasizes that every target chosen and every program advanced begins and ends with the patients waiting for an answer. OncoPrecision describes its differentiation as the convergence of three forces on one mission. The first, patient-derived biology, uses what the company calls Patient Micro-Avatars™ to identify targets from real patient tumor biology rather than population databases, starting where resistance is already happening. The second, AI-enhanced discovery, applies computational modeling to accelerate target validation and antibody optimization, compressing the timeline from insight to clinical candidate. The third, first-in-class audacity, involves antibody-drug conjugates and bispecific antibodies engineered to exploit vulnerabilities that existing therapies cannot reach, with CD64 named as the starting point. The company states that each of its programs is built on the convergence of these three forces, and that medicines with a higher probability of clinical success begin at the center of that convergence. Its public materials direct visitors to explore its science and view its pipeline, indicating active therapeutic programs, though specific pipeline assets beyond the CD64 focus are not detailed in the supplied evidence. No information on funding, partnerships, ownership, leadership, or regulatory milestones is available in the provided sources. The company appears to be active and privately held based on the absence of any listing information, but this is not confirmed by the evidence.

Precision oncology company combining patient-derived tumor biology, AI-enhanced discovery, and first-in-class antibody engineering to develop therapies for blood cancers and hard-to-treat solid tumors.

• Antibody-drug conjugates (ADCs)

  Engineered to exploit vulnerabilities that existing therapies cannot reach, as part of the company's first-in-class approach.

• Bispecific antibodies

  Developed alongside ADCs to target novel biology, with CD64 named as an initial focus.

• Patient Micro-Avatars™

  A platform concept for identifying targets from real patient tumor biology rather than population databases.

1. 1OncoPrecision — Precision is personal.oncoprecision.bio
2. 2OncoPrecision (United States) - Wikidatawikidata.org